换一批
换一批First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors.
作者：
主题词
成年人(Adult);老年人(Aged);抗肿瘤药(Antineoplastic Agents);队列研究(Cohort Studies);剂量效应关系, 药物(Dose-Response Relationship, Drug);女(雌)性(Female);肝细胞生长因子(Hepatocyte Growth Factor);人类(Humans);输注, 静脉内(Infusions, Intravenous);男(雄)性(Male);中年人(Middle Aged);分子靶向治疗(Molecular Targeted Therapy);肿瘤(Neoplasms);重组融合蛋白质类(Recombinant Fusion Proteins);肿瘤微环境(Tumor Microenvironment);血管内皮生长因子A(Vascular Endothelial Growth Factor A);青年人(Young Adult)
DOI
10.1200/JCO.20.00596
PMID
33301375
发布时间
2024-02-10
- 浏览3
Journal of clinical oncology
145-154页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
